Investors may find better financial performance in Crescent Biopharma Inc (CBIO)

Crescent Biopharma Inc [CBIO] stock is trading at $12.92, down -0.15%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CBIO shares have gain 3.44% over the last week, with a monthly amount drifted -6.38%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Crescent Biopharma Inc [NASDAQ: CBIO] stock has seen the most recent analyst activity on August 25, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $26. Previously, H.C. Wainwright started tracking the stock with Buy rating on August 11, 2025, and set its price target to $25. On July 14, 2025, Wedbush initiated with a Outperform rating and assigned a price target of $27 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $28 on June 25, 2025. Cantor Fitzgerald initiated its recommendation with a Overweight. TD Cowen downgraded its rating to Hold for this stock on July 26, 2024. In a note dated December 22, 2023, CapitalOne initiated an Overweight rating and provided a target price of $12 on this stock.

Crescent Biopharma Inc [CBIO] stock has fluctuated between $10.83 and $63.00 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Crescent Biopharma Inc [NASDAQ: CBIO] shares were valued at $12.92 at the most recent close of the market. An investor can expect a potential return of 101.24% based on the average CBIO price forecast.

Analyzing the CBIO fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -1.03 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

For context, Crescent Biopharma Inc’s Current Ratio is 9.21. As well, the Quick Ratio is 9.21, while the Cash Ratio is 9.12.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.